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Objective: To investigate the efficacy of 17 ethnomedicinal plants belonging to Apocynaceae
family used in combination with 16 conventional antibiotics against non-multidrug resistant-,
multidrug resistant (MDR)-, and extensive drug resistant (XDR) Acinetobacter baumannii
(A. baumanniii. Methods: Antibacterial activity and resistance modifying ability of 272
combinations were determined by growth inhibition assays and further confirmed by time-kill
assay. Results: Among the combinations of the antibiotics with Apocynaceae ethanol extracts
on this pathogen, 15 (5%) had synergistic effects, 23 (8%) had partial synergistic effects and 234
(86%) had no effects. Synergistic activity was observed mostly when the Apocynaceae extracts
were combined with rifampicin or cefazolin. Interestingly, 10 out of 17 combinations between
the extracts and rifampicin displayed synergistic or partial synergistic behaviors. Holarrhena
antidysenterica extract was additionally tested to restore rifampicin activity against clinical
isolates of MDR and XDRA. baumannii. With respect to total or partial synergy, 70%was XDR
A. baumannii isolates and 66% was MDRA. baumannii isolates. Conclusions: Holarrhena
antidysenterica extract clearly demonstrated the ability to restore rifampicin activity against both
A. baumannii ATCCI9606 and clinically isolated A. baumannii. Additional studies examining its
active principles as well as mechanisms of actions such as the effects on efflux pumps and outer
membrane permeability alterations are recommended.
1. Introduction
Increasing prevalence of multidrug resistant (MDR)
bacteria and limited treatment options have necessitated
the discovery of new antibacterial and resistance modifying
agents. Resistance modifying agents (RMAs) are compounds
which potentiate the activity of an antibiotic against a
resistant strain and may also target and inhibit MDR
meohanismsltl. An application of a RMA with a conventional
antibiotic is well accepted. Augmentin® is an important
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example which uses a combination of amoxicillin and a
microbial-derived beta-lactamase inhibitor as a RMA
(clavulanatejlzl, Recent experiments have additionally
demonstrated that molecules capable of blocking the
action of efflux pumps have the potential to circumvent
antimicrobial resistancelsl, Stermitz et al reported for the
first time the synergistic effect of a plant-derived ineffective
antibacterial agent, berberine and a multi drug resistance
pump inhibitor, 5'-methoxyhydnocarpin produced by
Berberis species against S. aureus[4]. Furthermore, several
plant-derived alkaloids and polyphenols such as reserpine,
quinine, harmaline, piperine, epigallocatechin gallate,
tellimagrandin I, and rugosin B have been demonstrated to
act as efflux pump inhibitors for Gram positive pathogen[5J.
Recently, we have demonstrated that Holarrhena
antidysenterica (Linn) Wall. (Apocynaceae) possessed a
  Sasitorn Chusri et al./Asian Pacific Journal of Tropical Medicine (2014)456-461 457
Table 1
Medicinal properties and extraction yields of ethanol extracts of selected Apocynaceae ethnomedicinal plants.
Medicinal plants (Plant parts)           Medicinal properties Extraction yield (%; w/w)
Adenium obesum (Forssk.) Roem. & Schult. (Leaves) Anti-cancer activity[20]   1.85
Allamanda cathartica L. (Flowers) Treating malaria and jaundice[21]   4.79
Alstonia macrophylla Wall. (Bark) Body tonic and anti-fever agents[22]   2.76
Alstonia scholaris (L.) R.Br. (Bark) Treating asthma and cardiac[23]   4.43 
Alyxia reinwardtii BL. var. lucida Markgr. (Branch) Antioxidant activity[24]   4.51
Carissa spinarum L. (Branch) Wound healing activity[25]   3.50
Catharanthus roseus L. (Branch) Used for treating cancers[26]   6.14
Cerbera manghas L. (Bark) Anti-cancer activity[27] 12.20
Cerbera odollam Gaertn. (Bark) Anti-cancer activity[28] 15.46
Holarrhena antidysenterica (L.) Wall. (Bark) Antibacterial activity[29]   2.72
Holarrhena curtisii King & Gamble (Branch) Leishmanicidal activities[30]   2.51
Nerium oleander L. (Branch) Treating skin diseases[31]   4.52
Plumeria obtusa (Bark) Treating skin diseases[32]   6.75
Plumeria rubra L. (Bark) Antibacterial activity[33]   7.52
Rauvolfia serpentina (L.) Benth. ex Kurz (Root) Antibacterial activity[34]   1.78
Thevetia peruviana (Pers.) K. (Bark) Antidiarrhoeal and antimicrobial activities[35] 11.66
Wrightia tomentosa Roem. & Schult. (Branch) Antibacterial activity[36]   2.75
i l i l -
remarkable RMA ability in combination with novobiocin
against Acinetobacter baumannii (A. baumannii) ATCC
19606[6].
To our knowledge, there is no report on the RMA activity of
other ethnomedicinal plants from the family Apocynaceae
as well as relatively few studies have been carried out to
evaluate RMA activities of plant-derived compounds on A.
baumannii. Therefore, this study was aimed to investigate
the RMA activity of medicinal plants belonging to the family
Apocynaceae in combination with conventional antibiotics
against A. baumannii ATCC 19606and a collection of clinical
A. baumannii isolates.
2. Materials and methods
2.1. Bacterial strains and culture condition
Clinically isolated A. baumannii isolates were obtained
from Songklanakarin Hospital from pus (n=I), blood (n=2),
sputum (n=5), body fluid (n=4), and urine (n=7) samples of
infected patients. A. baumannii ATCC 19606 was employed
in this study as a quality control strain. The strains were
cultured on tryptic soy agar (TSA) (Difco Laboratories,
Detroit, MI) and incubated at 37 ·C overnight. Colonies from
the plates were grown in Mueller Hinton broth (MHB) (Difco
Laboratories, Detroit, MI) at 37 "Cfor 18-24 h and adjusted to
McFarland standards No. 0.5. The suspensions were further
diluted with MHB to obtain inocula containing lx106 CFU/mL.
Susceptibility test was performed by the disk diffusion
method according to Clinical and Laboratory Standard
Institute (CLSI) recommendations[7J. MDR phenotypes
were defined as isolates resistant to at least three different
antimicrobial classes and the isolates resistant to all tested
agents were classified as extensive drug resistant (XDR)
phenotypeslsl,
2.2. Medicinal plant materials and extraction
Seventeen selected plant species belonging to the
Apocynaceae family were selected based on their potential
use in folk medicine for treatments of diseases, or known
to have antimicrobial activities as described in Table 1.
The medicinal plants were purchased from medicinal
herb retailers in Songkhla, Thailand and authenticated
by a taxonomist, Dr. Katesarin Maneenoon and voucher
specimens were deposited at the Faculty of Traditional Thai
Medicine, Prince of Songkla University, Hat Yai, Songkhla,
Thailand. The samples were washed with distilled water
and dried at 60 "C overnight. Ground plant material (100 g)
was macerated with 95% (v/v) ethanol (500 mL) for 7 days
at room temperature. After filtrations through a Whatman
No. 1 paper, the filtrates were concentrated using a rotatory
evaporator, and kept at 55 ·C until they were completely
dried. Yields (%; w/w) of each extracts were calculated as
the ratio of the weight of the extract to the weight of the
herb powder. A stock solution (200 mglmL) was prepared
by dissolving the dried extract in dimethylsulfoxide (DMSO)
(Merck, Germany).
2.3. Resistant modifying ability ofmedicinal plant extracts
Intrinsic anti-A. baumannii ATCC19606 activities
of the Apocynaceae extracts and a panel of selected
antibiotics consisting of cell wall inhibitors (penicillin,
oxacillin, ampicillin, imipenem, cefazolin, ceftazidime,
and vancomycin), protein synthesis inhibitors (amikacin,
gentamicin, streptomycin, fusidic acid, erythromycin, and
tetracycline), DNA synthesis inhibitors (novobiocin and
ciprofloxacin), and RNA synthesis inhibitors (rifampicin)
were determined by growth inhibition assays as previously
describedlsl, Briefly, the culture, containing ixio'
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Table 2 
Intrinsic anti-Acinetobacter activitya of Apocynaceae ethnomedicinal plants.
Bacterial growth inhibition (%)b No. of Apocynaceae (Plant species)
 0-25 3 (Allamanda cathartica; Cerbera manghus; Thevetia peruviana)
26-49 8 (Adenium obesum; Catharanthus roseus; Holarrhena antidysenterica; Holarrhena curtisii; Nerium oleander; 
Plumeria obtusa; Plumeria rubra; Wrightia pubescens)
50-75 4 (Alstonia scholaris; Alyxia reinwardtii; Cerbera odollam; Rauvolfia serpentine)
76-100 2 (Alstonia macrophylla; Carissa spinarum)
aAn antibacterial activity of phytochemicals is considered to be significant if MIC values are below 100 毺g/mL for crude extract and 10 毺g/mL 
for pure compounds[37]. 
bThe percentage inhibition of bacterial growth was calculated by using the equation:
Bacterial growth inhibition (%) = (ODcontrol-ODtest) /ODcontrol ×100. Where, ODcontrol represents the optical density at 620 nm of the control culture 
in MHB containing 1% (v/v) DMSO, ODtest represents the optical density at 620 nm of the culture in MHB containing 1 mg/mL of the ethanol 
extract.  The ODtest of respective blanks having only the extract was subtracted to give the final ODtest. 
i l -
plate containing 50 fL L of the extract (1 000 fL g/ml.) or
the antibiotic and 50 fL L of MHB. The antibiotics were
purchased from Becton Dickinson Microbiology Systems
(Sparks, MD, USA), Difco (Detroit,MI,USA) or made using the
laboratory collection of antibiotics.
The intrinsic antibacterial activity was exhibited as the
percentage of growth inhibition (GI) after incubation at 37 ·C
for 18 h and calculated from the following equation:
GI (%) = (ODcontrol-ODte,J/ODcontrolxl00. (1)
where, ODcontrol is optical density (00) 620 nm of bacteria
culture in MHB supplemented with 1% (v/v) DMSO as a
positive control and ODte,t is 00 620 nm of the bacterial
culture in MHB supplemented with the tested agent. The
ODte,t of respective blanks having only the extract was
subtracted to give the final ODte,t. GIA and GIE represent the
percentage inhibition of bacterial growth of the antibiotic
and extract, respectively.
Resistance modifying ability of each extract was observed
by adding of 50 fL L of the tested extract into the tested
plate supplemented with the antibiotic instead of MHB. This
biological activity was exhibited as the percentage of growth
inhibition as well but calculated from the followingequation:
%Growth inhibition of the combination (Glc) =ODcontrol-
ODtesJIODcontrolx100. (2)
where, ODcontrol is 00 620 nm of the positive control culture
and ODte,t is 00 620 nm of the bacterial culture in MHB
supplemented with the extract in combination with the
antibiotic.
The interpretation of the combination was classified as
synergism when GIc/GIA and GIc/GIE ratios were ~2.0,
partial synergism when 1.5:S;the ratios<2.0, and no effect
when the ratios <1.5. Ellagic acid at 40 fL mollL was
included as a positive control RMA in combination with
erythromycin, novobiocin, and rifampicin against A.
baumannii ATCCI9606.
The efficacy of combination therapy of the promising
medicinal plants in combination with the antibiotics was
additionally determined against 19 clinically isolated A.
baumannii isolates using the growth inhibition assay as
described above and further confirmed by a time-kill assay.
3. Results
In this present investigation, the growth inhibition assay
was employed to develop another approach for combating A.
baumannii infections using medicinal plants to potentiate
the activity of antibiotics. Independently, 15 out of 17 tested
ethanol extracts at concentration of 1 000 fL g/mL displayed
low inherent anti-A. baumannii activity (% of bacterial
growth inhibition was less than 75%) (Table 2). Only Alstonia
macrophylla and Carissa spinarum which completely
inhibited the bacterial growth at this concentration
possessed moderate antibacterial activity.
From 272 combinations tested between 17 medicinal
plants and 16 antibiotics, 15 (5%) showed synergism, 23
(8%) had partial synergistic interaction, and 234 (86%) had
no effect. Synergistic activity was observed mostly when
the Apocynaceae extracts were combined with rifampicin
or cefazolin against A. baumannii ATCC19606. Synergistic
behaviors were displayed in cefazolin in combination
with Alstonia scholaris, Cerbera odollam, Holarrhena
antidysenterica, Nerium oleander, or Thevetia peruviana or
rifampicin in combination with Adenium obesum,Holarrhena
antidysenterica, Plumeria obtuse, Thevetia peruviana, or
Wrightiapubescens (Table 3).
The ability of a representative effective resistance
modifier, Holarrhena antidysenterica to potentiate the
antibacterial activity of rifampicin against clinically isolated
A. baumannii was additionally evaluated to explore the
potential of developing a promising RMA (Table 4). The
interaction between the ethanol extract and rifampicin was
synergistic and partially synergistic in 8 (42.1%) and 3 (15.8%)
isolates of A. baumannii tested, respectively. With respect
to total or partial synergy, 70%, 66%, and 33% of the isolates
were XDRA. baumannii, MORA. baumannii, and non-MRD
A. baumannii, respectively.
The synergistic effect of this combination was further
confirmed by time-kill assay as illustrated in Figure
1. At the tested concentration, the extract exhibited no
antibacterial potencies, but it was shown to be a powerful
RMA in combination with rifampicin against A. baumannii
ATCC 19606, non-MDR A. baumannii, and XDR A.
baumannii.
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Table 3
Resistance modifying ability of Apocynaceae ethanol extracts in combination with selected antibiotics against Acinetobacter baumannii ATCC 
19606.
Plant species
Number of synergy or partial synergy interactions [Antibioticsa; (GIC:GIA/GIC:GIE)
b]
Synergyc                            Partial synergyc 
Adenium obesum 1 RIF (2.8/2.0) 3 MEM (1.8/4.6), GEN (1.5/1.7), ERY (1.5/4.9)
Allamanda cathartica 0 - 1 FUS (1.7/3.3)
Alstonia macrophylla 0 - 0 -
Alstonia scholaris 1 KZ (21.6/7.9) 0 -
Alyxia reinwardtii 0 - 2 KZ (17.8/1.5), RIF (2.6/1.5)
Catharanthus roseus 0 - 1 STR (1.8/22.0)
Carissa spinarum 0 - 0 -
Cerbera manghus 3 MEM (3.5/4.7), GEN (4.2/2.6), ERY (2.4/4.3) 2 AMP (1.7/3.6), RIF (4.7/1.8)
Cerbera odollam 1 KZ (21.4/3.5) 5 PEN(2.4/1.9), OXA (2.2/1.9), AMP (2.3/1.7), VAN 
(2.7/1.5), RIF (2.0/1.9)
Holarrhena antidysenterica 3 KZ (21.4/3.5), STR (3.9/9.5), RIF (2.7/3.0) 0 -
Holarrhena curtisii 0 - 1 KZ (11.9/1.6)
Nerium oleander 1 KZ (15.7/2.7) 1 RIF (1.7/2.0)
Plumeria obtusa 1 RIF (2.0/4.2) 0 -
Plumeria rubra 0 - 2 GEN (1.6/2.3), RIF (1.7/1.5)
Rauvolfia serpentin 0 - 0 -
Spirolobium cambodianum 0 - 0 -
Thevetia peruviana 3 KZ (21.1/18.4), FUS (2.2/2.3), RIF (2.1/6.2) 0 -
Wrightia pubescens 1 RIF (2.0/2.1) 5 MEM (1.7/6.4), KZ (1.8/35.3), GEN (1.8/3.1), STR 
(1.9/24.0), ERY (1.9/9.0),
aPEN=Penicillin G; OXA=Oxacillin; AMP=Ampicillin; MEM=Meropenem; KZ=Cephazolin; VAN=Vancomycin; GEN=Gentamicin; 
STR=Streptomycin; FUS=Fusidic acid; ERY=Erythromycin; RIF=Rifampicin.
bGIC represents the percentage inhibition of bacterial growth of tested antibiotics in combination with the extracts. GIA and GIE represent the 
percentage inhibition of bacterial growth of the antibiotics and the extracts, respectively. 
cCombinations were classified as synergistic effects if both GIC:GIA and GIC:GIE ratios were 曒2.0, partially synergetic effects if 1.5曑the 






























































































Figure 1. Time-kill activities of Holarrhena antidysenterica (HA; 125 毺g/mL), rifampicin (Ri; 1/4 MIC), novobiocin (No; 1/4 MIC), the 
combination of Holarrhena antidysenterica and rifampicin (Ri+HA), and the combination of Holarrhena antidysenterica and novobiocin (No+HA) 
againt Acinetobacter baumannii ATCC 19606 (A), non-MDR A. baumannii (B), and XDR A. baumannii (C). Minimun inhibitory concentrations 
of Ri and No against A. baumannii ATCC 19606, non-MDR A. baumannii, and XDR A. baumannii were 0.63 and 6.25, 5.00 and 25.00, and 
1.25 and 6.25 毺g/mL, respectively.  
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Uses of rifampicin in combination with colistin have been
studied for the treatment of MDR A. baumannii infections.
Both in vitro studies and clinical studies were employed
to recommend the safety and clinical effectiveness of
rifampicin in combination with colistin against this
pathogen[lO-131. It was suggested that colistin probably
causes rapid permeabilization of the outer membrane, which
enhances penetration and activity of rifampicin. Similarly,
plant-derived compounds that act as permeabilizers such as
coriander oil (Coriandrum sativum)[14I, geraniol tHelichrysum
italicum)[151, and [6]-dehydrogingerdione and [lO]-gingerol
(Zingiber officinale)[161 have been shown to reduce the
resistance of A. baumannii to other antibiotics. Even though
antibacterial activity of Holarrhena antidysenterica and its
constituents have been reported, there is to our knowledge
no published scientific literature of RMA activity on
rifampicin of this plant or its constituents.
Rifampicin resistance in A. baumannii is related to the
synergistic interaction between modifications of antibiotic
permeability, enzymatic modification by rifampicin
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Table 4
Effects of Holarrhena antidysenterica ethanol extract (HA; 125 毺g/mL) as a resistant modifying agent for rifampicin (Ri; 0.5 毺g/mL) against 
clinically isolated A. baumannii.
MDR- A. baumannii isolates (Sources)a Antibiogram profileb
GI (%)c in the presence of
GIC:GIA/GIC:GIE
d
Ri (0.5 毺g/mL) HA (125 毺g/mL) 
NPRC AB002 (BF) SRISRSSSSS 13.2依1.3    13.6依1.1 1.0/1.0
NPRC AB003 (S) RRRRRRRRSR 40.8依1.4    35.7依1.0 2.5/2.9
NPRC AB004 (U) SRISISSSSS 89.2依1.2      2.0依1.7 1.1/7.0
NPRC AB005 (U) RRRRR-RSIS 19.2依0.6  -21.0依1.5  1.8/1.7
NPRC AB010 (B) RRRRRRRRSR 30.7依1.8    35.5依3.7 1.6/1.4
NPRC AB011 (U) RRRRRRRRIR 37.2依0.5    37.3依1.3 1.0/1.0
NPRC AB013 (B) RRRRRRRRRR 17.8依2.6    37.9依2.9 4.8/2.3
NPRC AB014 (U) SRRSR-SRIR 19.0依4.1    22.0依2.8 4.4/3.8
NPRC AB015 (U) RRRRR-RRRR 25.3依0.7    23.0依1.4 2.1/2.3
NPRC AB016 (U) SRRSRRSSSS 51.8依1.9    23.8依5.0 1.2/2.7
NPRC AB017 (BF) RRRRRRRRRR 64.7依0.9    56.1依1.1 1.6/1.9
NPRC AB018 (S) RRRRRRRRRR 32.8依2.4    34.8依2.0 2.0/1.9
NPRC AB019 (S) RRRRRRRRRR 33.3依0.8    30.0依0.8 2.3/2.5
NPRC AB021 (S) SRISR-SRSR 40.7依2.8    27.5依1.6 2.1/3.2
NPRC AB022 (U) RRRRRRRRRR 18.1依1.6    39.2依1.1 2.1/0.4
NPRC AB024 (BF) -RRR-R-R-- 57.9依0.9    27.8依1.9 1.8/3.7
NPRC AB026 (S) RRRRRRRRSR 34.4依0.7    37.3依0.8 4.7/3.0
NPRC AB028 (BF) RRRRRRRRIR 35.9依1.5    28.8依1.0 2.1/2.6
NPRC AB029 (P) SRSSSSSSSS 17.4依4.8    27.5依3.8 1.4/8.7
aClinically isolated A. baumannii were obtained from pus (P), blood (B), sputum (S), body fluid (BF), and urine (U) samples of infected patients. 
bThe antibiogram profile is the susceptibility results for amikacin, ampicillin, cefotaxime, cefazolin, cefuroxime, ciprofloxacin, gentamicin, 
imipenem, cephoperazon/sulbactam, and meropenem.
cGI represents the percentage inhibition of bacterial growth of the tested compounds. 
dCombinations were classified as synergistic effects (GIC:GIA and GIC:GIE ratios 曑2.0), partially synergetic effects (1.5曑GIC:GIA and GIC:GIE 
ratios<2.0), indifferent effects (GIC:GIA and GIC:GIE ratios <1.5). GIA, GIE, and GIC represent the percentage inhibition of bacterial growth of Ri, 
HA, and the Ri+HA combination, respectively. 
i l -
t s t ; f1. ) r i i i; f1. )
- )" ra il " r lc: I) lc d. f1. i f1. i
) ± ± .
± ±
) ± ± 1 .
) ± . ±
OIO ) ± ± .
OlI ) ± ± .
) ± ±
0l ) - ± ±
l ) - ± ±
0l ) S ± ± .









" linically , ), ), )
bThe ilit , li , i
/ l t , .
' th s.
d o bi i ti t lc lc: I ~2.0), ti t 1.5~Glc: IA lc: I
, r t t lc lc: I . , , lc th Hi,
i ti , .
ADP-ribosyl-transferase (arr-2), or mutation in rpoB[17-
191. A recent finding by Giannouli et al proposed that the
combined treatment with colistin/rifampicin versus colistin
alone were evident only in A. baumannii strains with no
chromosomal mutations in RNA polymerase ~ -subunit
rpoB target genelttl, Interestingly, phenylalanine arginine
~ -naphthylamide (PA ~ N), an efflux pump inhibitor,
reduced the minimun inhibitory concentration of
rifampicin at 256 p. g/mL by approximately 30-fold in
A. baumannii isolate that showed no mutation in the rpoB
target genelttl.
The present results indicate that the ethanol extract
of Holarrhena antidysenterica is a promising resistance
modifying agent for rifampicin against A. baumannii, due to
its synergistic effect in combination with rifampicin against
both A. baumannii ATCC19606 and clinically isolated
A. baumannii. The findings may lead to development
of an effective alternative treatment in combating the
antimicrobial resistance in A. baumannii. Therefore, the
mechanisms of action of this combination as well as the
active constituents of Holarrhena antidysenterica should be
further investigated.
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